Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228681 · ClinicalTrials.gov registry record · Phase 2
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
A Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer, sponsored by GOG Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 20
- Study locations
NCT02228681 is a Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer that has completed, run by GOG Foundation. The registered enrollment target is 74 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02228681, a Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer, has completed, sponsored by GOG Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole
- DRUG Everolimus
- DRUG Medroxyprogesterone Acetate
Study Locations (20)
Georgia
- John B. Amos Cancer Center - Columbus
- Memorial Health University Medical Center - Savannah
Mississippi
- St. Dominic-Jackson Memorial Hospital - Jackson
- University of Mississippi Medical Center - Jackson
New Mexico
- New Mexico Cancer Alliance - Albuquerque
- Memorial Medical Center-Cancer Center - Albuquerque
New York
- Women's Cancer Care Associates - Albany
- SUNY Downstate Medical Center - Brooklyn
Ohio
- University Hospital Case Medical Center - Cleveland
- Ohio State University - Columbus
Colorado
- University of Colorado - Anschutz Cancer Pavilion - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-05-21 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228681
The ClinicalTrials.gov registry entry for NCT02228681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced, Persistent, or Recurrent Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT02228681 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Georgia, Mississippi, New Mexico.
Frequently Asked Questions
What is clinical trial NCT02228681 about?
NCT02228681 is a clinical study titled "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer". The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug co...
What is the current status of trial NCT02228681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2015-05-21. Estimated completion is 2024-08-22.
What conditions does trial NCT02228681 study?
This clinical trial studies the following conditions: Advanced, Persistent, or Recurrent Endometrial Cancer.
What interventions are being tested in trial NCT02228681?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole (DRUG), Everolimus (DRUG), Medroxyprogesterone Acetate (DRUG).
Who is sponsoring clinical trial NCT02228681?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02228681 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.